| Literature DB >> 29636911 |
Alyssa M West1, Peter J Teska2, Caitlinn B Lineback1, Haley F Oliver1.
Abstract
Background: Transmission of healthcare-associated infections caused by antibiotic- and multi-drug resistant (MDR) pathogens (e.g. Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa) are a major concern in patient care facilities. Disinfectant usage is critical to control and prevent pathogen transmission, yet the relationships among strain, disinfectant type, contact time, and concentration are not well-characterized. We hypothesized that there would be significant differences in disinfectant efficacy among clinically relevant strains under off-label disinfectant conditions, but there would be less no differences among at registered label use concentrations and contact times. The purpose of this study was to quantify the effect of disinfectant concentration and contact time on the bactericidal efficacy of clinically relevant strains of S. aureus and P. aeruginosa.Entities:
Keywords: Concentration; Disinfectant; Label; MRSA; Pseudomonas
Mesh:
Substances:
Year: 2018 PMID: 29636911 PMCID: PMC5883281 DOI: 10.1186/s13756-018-0340-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Characteristics of Staphylococcus aureus strains used in study
| Species of Microorganism | ATCC Strain Name | PFGE Type | SCCmec Type | Isolation Source | |
|---|---|---|---|---|---|
| Methicillin-resistant | ATCC BAA-1717 | USA 300 | Type IV | Positive | Adolescent patient with severe sepsis |
| Methicillin-resistant | ATCC BAA-1761 | USA 100 | Type II | Negative | Human Subject |
| Methicillin-resistant | ATCC BAA-1720 | USA 200 | Type II | Negative | Hospital acquired |
| Methicillin-resistant | ATCC BAA-1754 | USA 600 | Type IV | Negative | Human Subject |
|
| ATCC CRM-6538 | – | – | – | Human Lesion |
Characteristics of Pseudomonas aeruginosa strains used in study
| Species of Microorganism | ATCC Strain Name | Isolation Source | Antibiotic Resistance |
|---|---|---|---|
|
| ATCC BAA-2108 | Sputum Sample, human | AMX, AMP, CFZ, CXM, CAE, CTX, FOX, IPM, NIT, TGC, and TMP |
|
| ATCC BAA-2112 | Sputum Sample, human | AMX, AMP, CFZ, CLO, CXM, CAE, CTX, FOX, CRO, NIT, TGC, and TMP |
|
| ATCC BAA-2113 | Sputum Sample, human | AMX, AMP, CFZ, CLO, CXM, CAE, CTX, FOX, CRO, NIT, TGC, and TMP |
|
| ATCC BAA-2114 | Sputum Sample, human | AMX, AMP, TZP, CFZ, CLO, CXM, CAE, CTX, FOX, CRO, NIT, TGC, and TMP |
|
| ATCC 15442 | Animal room water bottle | – |
Fig. 1Log10 reduction values of each bacterial strain for a given disinfectant used at label conditions. Letters above bars indicate statistical grouping and significant differences among strains. a: Bactericidal efficacy of Virex Tb (Quat-based) against various MRSA and P. aeruginosa strains at label conditions (three-minute contact time). b: Bactericidal efficacy of Avert (Chlorine-based) against various MRSA and P. aeruginosa strains at bactericidal label conditions (one minute contact time). c: Bactericidal efficacy of Avert (Chlorine-based) against various MRSA and P. aeruginosa strains at C. difficile sporicidal label conditions (four-minute contact time). d: Bactericidal efficacy of Oxivir 1 (AHP-based) against various MRSA and P. aeruginosa strains at label conditions (one minute contact time)
Fig. 2Effect of varying disinfectant concentration on the bactericidal efficacy of three disinfectants at label concentration. a: Bactericidal efficacy of Virex Tb (Quat-based) against various MRSA strains. b: Bactericidal efficacy of Virex Tb (Quat-based) against various P. aeruginosa strains. c: Bactericidal efficacy of Avert (Chlorine-based) against various MRSA strains. d: Bactericidal efficacy of Avert (Chlorine-based) against various P. aeruginosa strains. e: Bactericidal efficacy of Oxivir 1 (AHP-based) against various MRSA strains. Panel F: Bactericidal efficacy of Oxivir 1 (AHP-based) against various P. aeruginosa strains
Fig. 3Effect of varying disinfectant contact time on bactericidal efficacy of three disinfectants at label concentration. a: Bactericidal efficacy of Virex Tb (Quat-based) against various MRSA strains. b: Bactericidal efficacy of Virex Tb (Quat-based) against various P. aeruginosa strains. c: Bactericidal efficacy of Avert (Chlorine-based) against various MRSA strains. d: Bactericidal efficacy of Avert (Chlorine-based) against various P. aeruginosa strains. e: Bactericidal efficacy of Oxivir 1 (AHP-based) against various MRSA strains. Panel F: Bactericidal efficacy of Oxivir 1 (AHP-based) against various P. aeruginosa strains